Now that the power of mutant p53 as a predictive/prognostic marker in breast cancer has been established, the complete characterization of mutant p53 contribution to tumorigenesis will require a combination of oncogenomic approaches, for example copy number analyses, mutational studies and expression profiling (protein coding genes and microRNAs) on a large number of patients. This evidence concerns the gene TP53 and breast cancer.